With $3 billion, Hal Barron and other biotech veterans launch a disease ‘reversal’ company
Altos Therapeutics will bring together some of the biggest names in biotech and a vision for reprogramming the machinery of living cells.
Read The StoryBiotech
Inside the discoveries, personalities, and deals driving drug development. Sign up for The Readout newsletter to get the latest on biotech delivered to your inbox. And subscribe to STAT+ to access daily, market-moving coverage of the biotech sector — from startup funding to clinical trial readouts
With its Alzheimer’s drug in turmoil, Biogen eyes a list of potential acquisitions
A new biotech startup looks to sidestep a key problem with CAR-T cancer therapies
Why Biogen’s Medicare mess is bad for the pharmaceutical industry
First transplant of a genetically altered pig heart into a person sparks ethics questions
All Coverage
advertisement
